2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-115922
    Anti-inflammatory agent 10 2910876-55-8 98%
    Anti-inflammatory agent 10 (compound 30) is a tilomisole-based benzimidazothiazole derivative. Anti-inflammatory agent 10 expresses activity on COX-2 enzyme more than COX-1. Anti-inflammatory agent 10 is orally active.
    Anti-inflammatory agent 10
  • HY-115923
    Nur77 modulator 2 2055829-03-1 98%
    Nur77 modulator 2, a Nur77 modulator (Kd of 0.35 μM), is a potent and orally active inflammation inhibitor. Nur77 modulator 2 modulates the colocalization of Nur77 at mitochondria.
    Nur77 modulator 2
  • HY-115927
    8A8 2766594-12-9 98%
    8A8 is a potent proinflammatory factor NO inhibitor with an IC50 of 4.7 μM. 8A8 also significantly inhibits LPS-induced HaCat cell proliferation.
    8A8
  • HY-115934
    COX-2-IN-7 98%
    COX-2-IN-7 (compound 4a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 6.585 uM. COX-2-IN-7 has higher COX-2 selectivity than Celecoxib. COX-2-IN-7 shows good in vivo anti-inflammatory and low ulcerogenic activity.
    COX-2-IN-7
  • HY-115935
    COX-2-IN-8 98%
    COX-2-IN-8 (compound 6a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 6.585 uM. COX-2-IN-8 has higher COX-2 selectivity than Celecoxib. COX-2-IN-8 shows good in vivo anti-inflammatory and low ulcerogenic activity.
    COX-2-IN-8
  • HY-115936
    COX-2-IN-9 98%
    COX-2-IN-9 (compound 7a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 10.17 uM. COX-2-IN-9 has higher COX-2 selectivity than Celecoxib. COX-2-IN-9 shows good in vivo anti-inflammatory and low ulcerogenic activity.
    COX-2-IN-9
  • HY-115944
    BTK-IN-9 2361192-21-2 98%
    BTK-IN-9 is a reversible BTK inhibitors with potent antiproliferative activity in mantle cell lymphoma. BTK-IN-9 specifically disturbs mitochondrial membrane potential and increases reactive oxygen species level in Z138 cells. BTK-IN-9 also induces cell apoptosis in Z138 cells.
    BTK-IN-9
  • HY-115959
    Anticancer agent 34 2379335-06-3 98%
    Anticancer agent 34 (compound 9), a sulfonylurea derivative, is a potent antimicrobial and anticancer agent. Anticancer agent 34 inhibits the microbial growth of B. mycoides, E. coli, and C. albicans with a MIC between 0.156 and 0.039 mg/ml. Anticancer agent 34 inhibits A549, PC3 cell growth with IC50s of 8.4 µg/ml, 7.8 µg/ml, respectively.
    Anticancer agent 34
  • HY-115961
    Anticancer agent 36 2902563-76-0 98%
    Anticancer agent 36 (compound 11), a sulfonylurea derivative, is a potent antimicrobial and anticancer agent. Anticancer agent 36 inhibits the microbial growth of B. mycoides, E. coli, and C. albicans with a MIC between 0.156 and 0.039 mg/L. Anticancer agent 36 inhibits A549, PC3 cell growth with IC50s of 19.7 µg/mL, 11.9 µg/mL, respectively.
    Anticancer agent 36
  • HY-115966
    COX-1/2-IN-1 2358849-47-3 98%
    COX-1/2-IN-2 is a potent COX1/2 inhibitor. COX-1/2-IN-2 exhibits significant inhibitory effect against COX-1 and COX-2 inhibitor with IC50 values of 13.9 ± 3.21 µM and 6.4±0.74 µM, respectively.
    COX-1/2-IN-1
  • HY-115967
    COX-1/2-IN-2 2882832-86-0 98%
    COX-1/2-IN-2 is a potent COX1/2 inhibitor. COX-1/2-IN-2 exhibits significant inhibitory effect against COX-1 and COX-2 inhibitor with IC50 values of 9.7 ± 0.09 µM and 4.6 ± 1.45 µM, respectively.
    COX-1/2-IN-2
  • HY-115971
    Anti-Trypanosoma cruzi agent-1 2854299-38-8 98%
    Anti-Trypanosoma cruzi agent-1 (Compd E5) posseses anti-T. gondii activity.
    Anti-Trypanosoma cruzi agent-1
  • HY-115972
    Anti-Trypanosoma cruzi agent-2 2863602-85-9 98%
    Anti-Trypanosoma cruzi agent-1 (Compd 3b), selective compound against NINOA trypomastigote (IC50 = 0.51 µM) and INC-5 epimastigote form (IC50 = 3.06 µM), posseses anti-T. gondii activity.
    Anti-Trypanosoma cruzi agent-2
  • HY-115976
    COX-2-IN-10 98%
    COX-2-IN-10 is a potent COX-2 inhibitor. COX-2-IN-10 inhibits the production of PGE2 in concentration dependent manner (IC50=2.54 µM). COX-2-IN-10 inhibits the expression of iNOS and COX-2 on mRNA and protein level . COX-2-IN-10 inhibits the production of IL-6, TNF-α and IL-1β.
    COX-2-IN-10
  • HY-115977
    Aldose reductase-IN-3 1390616-76-8 98%
    Aldose reductase-IN-3 (Compound 5) is a potent and moderately selective inhibitor of aldose reductase (AR) with an IC50 of 3.99 μM. Aldose reductase has recently emerged as a molecular target that is involved in various inflammatory diseases, including sepsis. Aldose reductase-IN-3 has the potential for the research of sepsis.
    Aldose reductase-IN-3
  • HY-116015
    Dihomo-γ-Linolenic acid methyl ester 21061-10-9 98.00%
    Dihomo-γ-Linolenic acid methyl ester is an n-6 polyunsaturated fatty acid that is mainly metabolized to an anti-inflammatory eicosanoid, prostaglandin (PG) E1, via the cyclooxygenase (COX) pathway. Anti-inflammatory and anti-proliferative effects.
    Dihomo-γ-Linolenic acid methyl ester
  • HY-116033
    BMS-363131 384829-65-6 98%
    BMS-363131 is a selective inhibitor for tryptase, with an IC50 <1.7 nM. BMS-363131 is hydrolytic stable at pH=7 and pH=9. BMS-363131 attenuates the astham in a guinea pig model.
    BMS-363131
  • HY-116050
    17(S)-HETE 183509-25-3 98%
    17S-HETE is arachidonic acid metabolite through cytochrome P-450 pathways. 17S-HETE serves as allosteric activator of the cytochrome P450 1B1 and inhibitor of ATPase, induces cardic hypertrophy.
    17(S)-HETE
  • HY-116088
    W123 1345982-24-2 98%
    W123, a FTY720 analog, is a competitive sphingosine 1-phosphate type 1 (S1P1) receptor antagonist. W123 is measured by GTPγS activation, MAPK recruitment, cell migration, and ligand-induced receptor internalization.
    W123
  • HY-116099
    ER-819762 1155773-15-1 98%
    ER-819762 is an orally active, highly selective prostaglandin E2 (PGE2) EP4 receptor antagonist with an EC50 of 70 nM against human EP4 receptor. ER-819762 can be used for rheumatoid arthritis research.
    ER-819762
Cat. No. Product Name / Synonyms Application Reactivity